Happy Tuesday Zingernation! It’s officially Super Bowl week! I’m sure you’re gonna get bombarded with various football (and T-Swift) themed storylines as we crawl closer to the game, so let’s talk about who else is making money in Vegas — and it sure as heck ain’t me.

The Las Vegas Sphere reported earnings yesterday, beating estimates on revenue. Tickets also went on sale for Dead and Co with John Mayer, who are doing 24 nights at the venue. Maybe next quarter we’ll be hearing about the “tie-dye shirt tailwinds” that boosted revenue above expectations.

Before we dive in, check out the company that’s revolutionizing how we diagnose heart problems.

And, did someone forward you this email? Click here to subscribe to this Benzinga newsletter and more.

YESTERDAY’S POLL RESULTS

Would you buy Apple's Vision Pro headset right now?

🟨🟨⬜️⬜️⬜️⬜️ 👍Yes

🟩🟩🟩🟩🟩🟩 👎 No

MARKET SNAPSHOT

Yesterday: What is this? Why is there red on my screen? Does someone know how to fix this? Oh yeah, I forgot stocks could go down too. A strong day for oil and the dollar led to minor losses in the major indices.

On Our Radar: Some Fed speak today, with various officials talking throughout the day. We will also hear from Eli Lilly, Spotify and more before the open, as well as Snap, Toyota and more after the close.

TOP STORY

WisdomTree CIO Says Other Big Tech Names Could Follow In Meta's Footsteps

Briefly: Jeremy Schwartz, the CIO of Wisdom Tree, joined Benzinga’s PreMarket Prep yesterday and told the hosts that Meta’s monster earnings report could be a sign of things to come from big tech companies.

Basically: Schwartz highlighted the company’s use of AI amid its cost-cutting measures as one of the drivers for Meta’s efficiency in the last quarter. Meta’s stock skyrocketed after its earnings report last Thursday, and is up more than 30% YTD.

Divvy Time: Schwartz also said that other tech companies could pull a page out of the Zuck Book, and start offering dividends. Typically, growing tech companies do not offer significant dividends, but Meta could be setting a new bar.

Quoted: "These big tech companies have been holding out. But it's interesting to see, you can have growth and return capital, not just through buy-backs … you can do it through dividends as well," Schwartz said.

Read On: Check out the full interview here.

PRESENTED BY ELICIO THERAPEUTICS

How Elicio Therapeutics Is Taking A Different Approach To Treating Cancers Like Colon Cancer, Expected To Be The Leading Killer Cancer By 2030

Elicio Therapeutics is at the forefront of cancer care with its AMP platform, transforming the landscape with cutting-edge immunotherapies. These innovations are designed not just to treat, but to strategically target and dismantle the very mutations that propel pancreatic and colon cancers.

The company's leading candidate, ELI-002, embodies this approach, aiming to deliver accessible, non-customized vaccines that promise a new dawn for cancer treatment efficacy and availability.

Though further studies are needed to confirm its efficacy, the shot could improve survival for colon cancer, expected to be the number one cause of cancer deaths for people between 20-49 years of age by 2030, and pancreatic cancer, which has just a 12% survival rate after five years.

There’s more, click here to keep reading.

FIVE ZINGERS

Two Steps Back?: Are car companies taking one step forward and two steps back when it comes to EVs? Here’s what one analyst says.

Let The Games Begin: If there’s one thing Redditors love to do, it’s speculate. Here’s what they’re saying is going to happen to Reddit’s stock when it hits the market.

Crystal Ball: The Simpsons has an incredibly impressive track record of making predictions years in advance… here’s the latest one. 

Gold Standard?: UBS is bullish on gold as we head into the spring. Here’s why the bank’s analyst thinks the precious metal is hitting $2,200 an ounce by EOY.

Investing Is HardBank: SoftBank has made some not-so-great calls throughout the past few years, but this one on Invitae might be the worst.

ONE FOR THE ROAD

Fed's Kashkari Echoes Powell's Hawkish Stance: 'Monetary Policy Is Not As Tight As We Would Have Assumed'

Briefly: Neel Kashkari, President of the Federal Reserve Bank of Minneapolis, said Monday that the Federal Reserve’s current monetary policy might not be as tight as previously assumed, given the evolving economic conditions.

So Basically: Kashkari said that we all got a little too used to a near zero-interest-rate environment and that where we’re at now isn’t as tight as people are making it out to be.

Super Bull: According to the Minneapolis Fed President, the threshold for what is considered neutral, or neither stimulative nor restrictive, monetary policy could be higher in the current context, providing the Fed with more room to maneuver before adjusting interest rates.

What Next: Read more here.

A MESSAGE FROM ELICIO THERAPEUTICS

Elicio Therapeutics (NASDAQ: ELTX) Reports Promising Progress In Cancer Vaccine Clinical Trials, Placing An Emphasis On The Lymphatic System

An estimated 609,820 people will die of cancer in the United States this year. Promising results from a 12-year-old clinical-stage biotechnology company have experts optimistic about the future of treating this deadly disease.

With its proprietary Amphiphile or “AMP” platform, Elicio Therapeutics Inc. has developed multiple cancer vaccine candidates that concentrate an array of different immunogens in the lymph nodes.

ELI-002 is Elicio’s lead clinical program for Kirsten rat sarcoma (KRAS) driven cancers caused by a mutation of the KRAS gene.

Click here to learn more and see what’s in store for Elicio Therapeutics in 2024.